- ￥5000
- GeneTex
- 美国
- GTX14477
- 2025年07月11日
- WB, ICC/IF, IP, ELISA
- Mouse
- Yeast
企业认证
相关产品推荐更多 >
![EPM2AIP1 antibody [1F11]](https://img1.dxycdn.com/2023/0711/451/6106825198874858761-14.jpg!wh200)
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant protein corresponding to aa1-147 mapping within the N-terminal, DNA binding domain of GAL4.
- 亚型：
IgG1
- 形态：
Liquid
- 保存条件：
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
- 克隆性：
Monoclonal
- 标记物：
Unconjugated
- 适应物种：
Yeast
- 保质期：
12 months from the shipping date of the product.
- 抗原来源：
Yeast
- 目录编号：
GTX14477
- 级别：
Primary Antibodies
- 库存：
Available
- 供应商：
GeneTex
- 宿主：
Mouse
- 应用范围：
WB, ICC/IF, IP, ELISA
- 浓度：
Batch dependent (Please refer to the vial label for the specific concentration.)
- 靶点：
Specific for the DNA binding domain of the S. cerevisiae GAL4 protein. The immunoreactive epitope maps within aa1-92 of GAL4.
- 抗体英文名：
Galectin 4 antibody [3G152]
- 抗体名：
Galectin 4 抗体 [3G152]
- 规格：
100 μg
WB analysis of various samples using GTX14477 Galectin 4 antibody [3G152].
Lane 1 : GAL4VP16 C-terminal fusion protein
Lane 2 : GAL4VP16 N-terminal fusion protein
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验ANTIBODY BINDING TO PROTEIN A AND PROTEIN G
Protein A, derived from the cell wall of Staphylococcus aureus , and protein G, derived from the cell wall of certain strains of b -hemolytic Streptococcci , binds the Fc region
Antibody Purification: Affinity Chromatography Protein A and Protein G Sepharose
G coupled to agarose. In the Subheading 3 there are also protocols for affinity purification using a specific ligand coupled to commercial matrices like CNBr- Sepharose 4-B and Affigel.
Analysis and Purification of Antibody Fragments Using Protein A, Protein G, and Protein L
Today, monoclonal antibodies (mAbs) form the largest category of biopharmaceuticals in clinical trials and their number is expanding rapidly (DataMonitor 2007). The antibodies or functional antibody fragments are being produced in artificial
技术资料暂无技术资料 索取技术资料
